Clinical trials: Eye Enucleation, open to volunteers
Urinary Retention, Benign Prostate Obstruction (BPO)
Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Urinary Retention
Benign Prostatic Obstruction (BPO) is a common condition in aging men that can lead to urinary retention, often requiring the use of an indwelling urinary catheter.
- Trial name
- NCT07603011
- Testing
- Laser Enucleation of the Prostate (HoLEP, ThuLEP, ThuFLEP)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Eskişehir Osmangazi University Medicine Faculty Hospital
BPH With Urinary Obstruction, Antibiotic Prophylaxis
Randomized Controlled Trial of Different Antibiotic Duration Prior to Prostate Enucleation Surgery
To compare the risk of infectious complications (UTI, pyelonephritis, sepsis, hospital admission, ED visits) for patients with an indwelling urinary catheter (urethral or suprapubic) or CIC receiving 3 or 7 days of peri-operative…
- Trial name
- NCT07209150
- Testing
- antibiotic prophylaxis
- Volunteers
- 250 people
- Sponsor
- Ohio State University
Locally Advanced Unresectable Uveal Melanoma
Neoadjuvant Tebentafusp for Uveal Melanoma
This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma.
- Trial name
- NCT06414590
- Testing
- Tebentafusp-Tebn
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Thomas Jefferson University
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Retinoblastoma
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
- Trial name
- NCT05080010
- Testing
- 3 cycles chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University